Results 61 to 70 of about 4,156,285 (177)

Identification of the Best Cut-Off Value of PIVKA-II for the Surveillance of Patients at Risk of Hepatocellular Carcinoma Development

Biology, 2023
Patients with cirrhosis are at risk of hepatocellular carcinoma (HCC) development and, according to current guidelines, should undergo surveillance by ultrasound at six month intervals.
Gian Paolo Caviglia, Maria Lorena Abate, Giulia Troshina, Patrizia Carucci, Emanuela Rolle, Alessandra Risso, Michela Emma Burlone, Alice Albè, Martina Crevola, Emma Clara Musso, Chiara Rosso, Angelo Armandi, Antonella Olivero, Rosalba Minisini, Giorgio Maria Saracco, Elisabetta Bugianesi, Mario Pirisi, Alessia Ciancio, Silvia Gaia   +18 more
doaj   +1 more source

Potenciál využitia galectinu-3 a PIVKA II v hepatológii / The potential use of galectin-3 and PIVKA II in hepatology

, 2022
SÚHRN Galectin-3 (GAL3) je biomarker fibrózy s prednostným využitím v kardiológii, pribúdajú práce popisujúce jeho využitie v nefrológii, hepatológii a pneumológii. PIVKA II je kandidátnym biomarkerom hepatocelulárneho karcinómu a iných chorôb pečene.
Jabor, Antonín, Franeková, Janka
openaire   +2 more sources

Surgical Outcomes and Recurrence Management in Borderline Resectable Hepatocellular Carcinoma: Implications for Multidisciplinary Strategies

Annals of Gastroenterological Surgery, Volume 10, Issue 4, Page 1143-1154, July 2026.
Multivariate analysis identified that up‐to‐7 out (p < 0.001), lymph node metastasis (p < 0.001), and non‐anatomical resection (p = 0.02) were independent predictors of cancer recurrence, while older age (p = 0.01), Child‐Pugh B (p < 0.001), up‐to‐7 out (p = 0.01), macrovascular invasion (p = 0.01), and lymph node metastasis (p < 0.001) were ...
Koichiro Haruki, Kenei Furukawa, Munetoshi Akaoka, Yuto Yamahata, Shinji Onda, Yoshihiro Shirai, Masashi Tsunematsu, Tomohiko Taniai, Michinori Matsumoto, Toru Ikegami   +9 more
wiley   +1 more source

Burnt‐Out MASLD Predicts Outcomes After Curative Resection for Hepatocellular Carcinoma

Liver International, Volume 46, Issue 7, July 2026.
ABSTRACT Background and Aims Hepatic steatosis often diminishes as metabolic dysfunction–associated steatotic liver disease (MASLD) progresses, leading to a so‐called ‘burnt‐out’ state. Whether this phenotype simply reflects advanced liver injury or represents a biologically distinct condition with prognostic relevance after hepatocellular carcinoma ...
Yukihiro Watanabe, Masayasu Aikawa, Yoshiki Murase, Takuya Oba, Yumiko Kageyama, Kenichiro Takase, Yuichiro Watanabe, Hiroaki Ono, Katsuya Okada, Kojun Okamoto, Isamu Koyama   +10 more
wiley   +1 more source

Association Between Multi‐Laboratory Parameters Pre‐ and Post‐Treatment and Pathological Features and Their Values in Clinical Decision in Primary Hepatic Carcinoma

Journal of Clinical Laboratory Analysis, Volume 40, Issue 11, June 2026.
Primary hepatic cancer (PHC), especially hepatocellular carcinoma (HCC), is still a significant burden worldwide. The efficacy of diagnosis, treatment response monitoring, and prognostication using laboratory biomarkers is still a challenge. This study analyzed multi‐laboratory parameters pre‐ and post‐treatment and their associations with clinical and
Xiaowei Chi, Weifang Liu, Zihan Liu, Jie Liu   +3 more
wiley   +1 more source

Enterococcus faecalis Extracellular Vesicles Deliver the Bacterial GTPase Obg to Hijack mTOR Signalling in Hepatocellular Carcinoma

Journal of Extracellular Vesicles, Volume 15, Issue 6, June 2026.
E. faecalis is enriched in HCC tissue and can promote liver tumourigenesis by activating mTOR signalling pathway. Obg derived from E. faecalis extracellular vesicles (EVs) is a GTPase physically interacts with mTOR, and acts as an interkingdom activator of mTOR. EF‐Obg expression level in HCC tissue correlates with poor prognosis in HCC patients.
Ning Ma, Xiaoshan Xie, Jiarui Wang, Zhikai Zheng, Huilin Jin, Xijie Chen, Xiaoling Huang, Haidan Luo, Yue Wei, Qihao Pan, Boyu Zhang, Jiaying Zheng, Peng Zhang, Fenghai Yu, Xue Liu, Zhi‐Min Zhang, Zhongguo Zhou, Xiangqi Meng, Mong‐Hong Lee   +18 more
wiley   +1 more source

The diagnostic performance of PIVKA-II in metabolic and viral hepatocellular carcinoma: A pilot study

, 2020
OBJECTIVE: Hepatocellular carcinoma (HCC) is a primary liver tumor derived from metabolic or viral chronic hepatitis, with few treatment options in advanced cases. New biomarkers that allow improving diagnosis and staging are widely desired. Here, we aim
DI GIACINTO F., GASBARRINI A., MARRONE G., RAPACCINI G. L., DE MATTHAEIS N., NAPODANO C., MIELE L., GRIECO A., BIOLATO M., CIASCA G., MARINO M., LIGUORI A., BASILE U., POCINO K.   +13 more
core   +1 more source

Prognostic Value of Pathological Response After Conversion Therapy and Salvage Surgery in Unresectable Hepatocellular Carcinoma

Liver International, Volume 46, Issue 6, June 2026.
ABSTRACT Background and Aims To evaluate the prognostic significance of pathological response in patients with initially unresectable hepatocellular carcinoma (uHCC) who underwent salvage resection after successful conversion with lenvatinib, anti‐PD‐1 antibodies, and locoregional therapy (LPLRT).
Qi‐Yu Chi, Xiao‐Di Gao, Mi Wang, Quan‐Yuan Liu, Yong‐Yi Zeng, Lan‐Fang Yang, Zi‐Jian Liu, Shuang‐Jia Wang, Shan‐Geng Weng, Zhi‐Bo Zhang   +9 more
wiley   +1 more source

Usefulness of PIVKA-II for diagnosis and evaluation of recurrence of hepatocellular carcinoma [PDF]

, 2017
Backgroud: Although alpha-fetoprotein (AFP) is most widely used tumor marker for hepatocellular carcinoma (HCC), the sensitivity is about 60~70% in advanced HCC. Furthermore, the specificity of AFP is relatively low. The aim of this study was to evaluate
안상훈, 이관식, 심명기, 김도영, 한광협, 김자경, 전재윤, 김경규, 백용한   +8 more
core  

Diagnostic Performance of AFP, AFP-L3, or PIVKA-II for Hepatitis C Virus-Associated Hepatocellular Carcinoma: A Multicenter Analysis

, 2022
Background and Aim: Alpha-fetoprotein (AFP), a lens culinaris agglutinin-reactive fraction of AFP (AFP-L3), is a protein that is induced by vitamin K deficiency or antagonist-II (PIVKA-II) that has been clinically used as a serum biomarker for early ...
Siyu Liu, Feng Shen, Guan, Mingcheng, Pawlik, Timothy M., Xu, Min, Zhu, Hong, Timothy M. Pawlik, Yang, Tian, Liyang Sun, Yongkang Diao, Tian Yang, Hao Xing, Min Xu, Lanqing Yao, Mingda Wang, Liu, Siyu, Xiangmin Tong, Wan Yee Lau, Yao, Lanqing, Tong, Xiangmin, Lau, Wan Yee, Wang, Mingda, Shen, Feng, Xing, Hao, Sun, Liyang, Diao, Yongkang, Mingcheng Guan, Hong Zhu   +27 more
core   +1 more source